Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oral Contraceptive Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.

NCT01251263
View directory record Official record
Conditions
Menstrual Migraines, Menstrual Bleeding, Menstrual Spotting
Interventions
Estradiol or Placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2010 · Synced Sep 25, 2026, 2:12 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)

NCT00682890
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS, Insulin Sensitivity
Interventions
placebo, metformin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

NCT05093205
View directory record Official record
Conditions
Healthy Adults
Interventions
PF-06882961, Atorvastatin, Midazolam, Levonorgestrel & Ethinyl Estradiol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study

NCT02817841
View directory record Official record
Conditions
Contraception
Interventions
15 mg E4/3 mg DRSP
Drug
Lead sponsor
Estetra
Industry
Eligibility
16 Years to 50 Years · Female only
Enrollment
2,148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021

NCT00544882
View directory record Official record
Conditions
Healthy
Interventions
DR-1021, Mircette®, Kariva®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Lawrenceville, New Jersey • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

NCT02832180
View directory record Official record
Conditions
Arthritis
Interventions
OC containing EE and NET, BMS-986142
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Miami, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.

NCT00196352
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
11
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Lincoln, Nebraska + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial of Immediate Versus Delayed Initiation of Oral Contraceptive Pills After Abortion

NCT00235534
View directory record Official record
Conditions
Abortion
Interventions
Immediate initiation of OCPs, Delayed initiation of OCPs
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2012 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 25, 2026, 2:12 AM EDT
Completed No phase listed Observational Results available

A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity

NCT05061472
View directory record Official record
Conditions
Contraceptive Usage, Overweight or Obesity, Body Weight Changes, Appetitive Behavior, Eating Behavior
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Timeline
2022 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

NCT00983957
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-790052, Ortho Tri-Cyclen®
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tempe, Arizona • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

NCT06820307
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine, DRSP/EE, NGM/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 25, 2026, 2:12 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Obesity and Oral Contraceptive Failure

NCT01944306
View directory record Official record
Conditions
Contraception, Fetal Growth Retardation, Infant, Small for Gestational Age, Obesity
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

US Ovulation Inhibition Study in Obese Women

NCT00873483
View directory record Official record
Conditions
Contraception
Interventions
Ethinylestradiol/Gestodene (BAY86-5016)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
6
States / cities
Tucson, Arizona • San Diego, California • Sandy Springs, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

NCT03783897
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305, Oral Contraceptive
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 25, 2026, 2:12 AM EDT
Withdrawn Phase 4 Interventional

Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients

NCT00826839
View directory record Official record
Conditions
Infertility
Interventions
Oral contraceptive pill and microdose lupron, E2 patch/antagonist
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women

NCT00125983
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Lopinavir/ritonavir, Ortho Novum 1/35, Ortho Evra
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 25, 2026, 2:12 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

NCT07808060
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Eloralintide, Combined oral contraceptive
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 25, 2026, 2:12 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effect of a Smartphone Application on Oral Contraceptive Adherence in College Females

NCT01947842
View directory record Official record
Conditions
Adherence to Oral Contraceptive Therapy
Interventions
Smartphone App Dosecast
Device
Lead sponsor
Belmont University
Other
Eligibility
18 Years to 29 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
Auburn, Alabama • Oxford, Mississippi • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Contraceptive (OC) Progestin Dose and Breast Proliferation

NCT00972439
View directory record Official record
Conditions
Oral Contraceptive
Interventions
Oral Contraceptive: Ortho-Novum® 1/35, Oral Contraceptive: Ovcon Fe®
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

NCT06071442
View directory record Official record
Conditions
Healthy Participants
Interventions
Vemircopan, Rosuvastatin, Metformin, Levonorgestrel / Ethinyl Estradiol, Carbamazepine
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 25, 2026, 2:12 AM EDT
Completed No phase listed Observational Results available

Same Day Oral EC and Implant Initiation

NCT04678817
View directory record Official record
Conditions
Contraception
Interventions
Etonogestrel contraceptive implant with oral levonorgestrel, Levonorgestrel intrauterine device, Copper T380A intrauterine device
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

NCT06380205
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Levonorgestrel/Ethinyl estradiol
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 25, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)

NCT00754065
View directory record Official record
Conditions
Contraception
Interventions
Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ortho Tri Cyclen Lo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
34
States / cities
Independence, Arizona • Phoenix, Arizona • Encinitas, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 25, 2026, 2:12 AM EDT